1
|
Stapleton JT. Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease? Front Immunol 2022; 13:887760. [PMID: 35707535 PMCID: PMC9190258 DOI: 10.3389/fimmu.2022.887760] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 05/03/2022] [Indexed: 12/25/2022] Open
Abstract
Two groups identified a novel human flavivirus in the mid-1990s. One group named the virus hepatitis G virus (HGV) and the other named it GB Virus type C (GBV-C). Sequence analyses found these two isolates to be the same virus, and subsequent studies found that the virus does not cause hepatitis despite sharing genome organization with hepatitis C virus. Although HGV/GBV-C infection is common and may cause persistent infection in humans, the virus does not appear to directly cause any other known disease state. Thus, the virus was renamed “human pegivirus 1” (HPgV-1) for “persistent G” virus. HPgV-1 is found primarily in lymphocytes and not hepatocytes, and several studies found HPgV-1 infection associated with prolonged survival in people living with HIV. Co-infection of human lymphocytes with HPgV-1 and HIV inhibits HIV replication. Although three viral proteins directly inhibit HIV replication in vitro, the major effects of HPgV-1 leading to reduced HIV-related mortality appear to result from a global reduction in immune activation. HPgV-1 specifically interferes with T cell receptor signaling (TCR) by reducing proximal activation of the lymphocyte specific Src kinase LCK. Although TCR signaling is reduced, T cell activation is not abolished and with sufficient stimulus, T cell functions are enabled. Consequently, HPgV-1 is not associated with immune suppression. The HPgV-1 immunomodulatory effects are associated with beneficial outcomes in other diseases including Ebola virus infection and possibly graft-versus-host-disease following stem cell transplantation. Better understanding of HPgV-1 immune escape and mechanisms of inflammation may identify novel therapies for immune-based diseases.
Collapse
Affiliation(s)
- Jack T. Stapleton
- Medicine Service, Iowa City Veterans Administration Healthcare, Iowa City, IA, United States
- Departments of Internal Medicine, Microbiology & Immunology, University of Iowa, Iowa City, IA, United States
- *Correspondence: Jack T. Stapleton,
| |
Collapse
|
2
|
Kovesdi I, Bakacs T. Therapeutic Exploitation of Viral Interference. Infect Disord Drug Targets 2021; 20:423-432. [PMID: 30950360 DOI: 10.2174/1871526519666190405140858] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2019] [Revised: 03/18/2019] [Accepted: 03/19/2019] [Indexed: 02/06/2023]
Abstract
Viral interference, originally, referred to a state of temporary immunity, is a state whereby infection with a virus limits replication or production of a second infecting virus. However, replication of a second virus could also be dominant over the first virus. In fact, dominance can alternate between the two viruses. Expression of type I interferon genes is many times upregulated in infected epithelial cells. Since the interferon system can control most, if not all, virus infections in the absence of adaptive immunity, it was proposed that viral induction of a nonspecific localized temporary state of immunity may provide a strategy to control viral infections. Clinical observations also support such a theory, which gave credence to the development of superinfection therapy (SIT). SIT is an innovative therapeutic approach where a non-pathogenic virus is used to infect patients harboring a pathogenic virus. For the functional cure of persistent viral infections and for the development of broad- spectrum antivirals against emerging viruses a paradigm shift was recently proposed. Instead of the virus, the therapy should be directed at the host. Such a host-directed-therapy (HDT) strategy could be the activation of endogenous innate immune response via toll-like receptors (TLRs). Superinfection therapy is such a host-directed-therapy, which has been validated in patients infected with two completely different viruses, the hepatitis B (DNA), and hepatitis C (RNA) viruses. SIT exerts post-infection interference via the constant presence of an attenuated non-pathogenic avian double- stranded (ds) RNA viral vector which boosts the endogenous innate (IFN) response. SIT could, therefore, be developed into a biological platform for a new "one drug, multiple bugs" broad-spectrum antiviral treatment approach.
Collapse
Affiliation(s)
- Imre Kovesdi
- ImiGene, Inc., Rockville, MD, USA,HepC, Inc., Budapest, Hungary
| | | |
Collapse
|
3
|
Zimmerman J, Blackard JT. Human pegivirus type 1 infection in Asia-A review of the literature. Rev Med Virol 2021; 32:e2257. [PMID: 34038600 DOI: 10.1002/rmv.2257] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 05/13/2021] [Accepted: 05/17/2021] [Indexed: 12/16/2022]
Abstract
The human pegivirus type 1 (HPgV-1)-as known as hepatitis G virus and GB virus C-is a common single-stranded RNA flavivirus. Because few studies have demonstrated an association between HPgV-1 infection and disease, screening for HPgV-1 is not performed routinely. Nonetheless, a beneficial impact of HPgV-1 infection on HIV disease progression has been reported in multiple studies. Given the burden of HIV in Asia and the complex interactions between viral co-infections and the host, we provide a comprehensive overview of the existing data from Asia on HPgV-1 infection, including the prevalence and circulating genotypes in all Asian countries with data reported. This review highlights the research conducted thus far and emphasizes the need for additional studies on HPgV-1 across the Asian continent.
Collapse
Affiliation(s)
- Joseph Zimmerman
- Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Jason T Blackard
- Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| |
Collapse
|
4
|
Ahmadi MH. Would the interference phenomenon be applied as an alternative option for prophylaxis against COVID-19? BIOIMPACTS : BI 2020; 11:169-172. [PMID: 34336604 PMCID: PMC8314034 DOI: 10.34172/bi.2021.12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/01/2020] [Revised: 09/01/2020] [Accepted: 09/12/2020] [Indexed: 12/23/2022]
Abstract
The coronavirus disease 2019 (COVID-19) is an emerged infectious disease characterized by a severe pneumonia leading to death in some cases. Currently, no licensed vaccines, drugs, or biologics have been confirmed to be absolutely effective in prophylaxis or treatment of this novel infection. Therefore, the treatment of this highly contagious disease remains a global concern and emergency. The viral interference is a competition phenomenon by which a primary virus infecting a cell prohibits the infection of the same cell by another (secondary) virus. The phenomenon has recently been indicated to be exploited for antiviral strategies. This strategy, particularly when there is no efficient drug against a viral infection, is of high importance. Some researchers have studied the application of the phenomenon among different viruses. In this paper, I discussed the possibility of the application of interference phenomenon in prophylaxis of the disease.
Collapse
|
5
|
Gao YW, Wan ZW, Wu Y, Li XF, Tang SX. PCR-based screening and phylogenetic analysis of rat pegivirus (RPgV) carried by rodents in China. J Vet Med Sci 2020; 82:1464-1471. [PMID: 32713889 PMCID: PMC7653312 DOI: 10.1292/jvms.19-0530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Rodent-borne pegiviruses were initially identified in serum samples from desert wood-rats in 2013, and subsequently in serum samples from commensal rats in 2014. However, the prevalence and phylogenetic characteristics of rodent pegiviruses in China are poorly understood. In this study, we screened serum samples collected from wild rats in southern China between 2015 and 2016 for the presence of rat pegivirus (RPgV) by PCR. Among the 314 serum samples from murine rodents (Rattus norvegicus, Rattus tanezumi, and Rattus losea) and house shrews (Suncus murinus), 21.66% (68/314) tested positive for RPgV. Out of these, 23.81% (62/219) of samples from R. norvegicus tested positive, which was significantly higher than that for the other species: 7.69% (1/13), 5.88% (2/34), and 6.25% (3/48) for R. tanezumi, R. losea, and S. murinus, respectively (χ2=18.91, P<0.001). Phylogenetic analysis revealed clustering of viral sequences in the main rodent clade. Analysis of the 3 near-full-length genome sequences of RPgV obtained in this study showed that these viruses exhibited mean nucleic acid and amino acid identities of 94.1% and 98.5% with Chinese RPgV strains, and 90.3 and 97.1% with an RPgV strain from the USA, respectively. This study provides novel insights into the geographic distribution of rodent pegiviruses in China, and identifies potential animal hosts for future studies of these pegiviruses.
Collapse
Affiliation(s)
- You-Wen Gao
- Department of Epidemiology, School of Public Health, Southern Medical University, 1838 Guangzhou North Road Guangzhou 510515, China
| | - Zheng-Wei Wan
- Department of Epidemiology, School of Public Health, Southern Medical University, 1838 Guangzhou North Road Guangzhou 510515, China
| | - Yue Wu
- Department of Epidemiology, School of Public Health, Southern Medical University, 1838 Guangzhou North Road Guangzhou 510515, China
| | - Xiu-Fen Li
- Department of Epidemiology, School of Public Health, Southern Medical University, 1838 Guangzhou North Road Guangzhou 510515, China
| | - Shing-Xing Tang
- Department of Epidemiology, School of Public Health, Southern Medical University, 1838 Guangzhou North Road Guangzhou 510515, China
| |
Collapse
|
6
|
Meng Y, Liu H, Bian N, Gong J, Zhong X, Huang C, Liang W, Xu H. In vitro study on human umbilical cord mesenchymal stem cells transfected with lentivirus-mediated hNIS-EGFP dual reporter gene and co-labeled with superparamagnetic iron oxide. Exp Ther Med 2018; 16:2208-2218. [PMID: 30186460 PMCID: PMC6122337 DOI: 10.3892/etm.2018.6505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2016] [Accepted: 05/05/2017] [Indexed: 01/10/2023] Open
Abstract
The aim of the present study was to establish a stem cell line for multi-mode imaging (in vivo fluorescence imaging, magnetic resonance imaging and 99mTc single-photon emission computed tomography) and to study the biological activity, stemness, proliferative activity and differentiation ability of superparamagnetic iron oxide (SPIO), human sodium/iodide symporter (hNIS) and enhanced green fluorescent protein (EGFP) co-labeled human umbilical cord mesenchymal stem cells (hUCMSCs). The EGFP reporter gene was selected to indirectly reflect the expression of target gene hNIS, and hUCMSCs were re-transfected with the successfully constructed recombinant plasmid pCMV-NIS-EF1-GFP-PGK-puro. When a stem cell line stably expressing hNIS and EGFP was obtained, the cells were incubated with 30 µg/ml SPIO to obtain hNIS, EGFP and SPIO co-labeled stem cells. The protein expressions of hNIS and EGFP were identified using western blot analysis, and the protein function of hNIS was identified by 125I influx and 125I efflux experiments. hNIS-EGFP-hUCMSCs were labeled with SPIO under the mediation of poly-L-lysine, and SPIO, hNIS and EGFP co-labeled hUCMSCs were established successfully. Staining with Prussian blue confirmed that 98% of cells were successfully labeled with SPIO. Western blotting results demonstrated positive hNIS and EGFP protein expression levels, and 125I influx and 125I efflux experiments confirmed that the protein function of hUCMSCs after expressing hNIS was normal. The uptake of 125I was higher in cell lines hNIS-EGFP-hUCMSCs than in control hUCMSCs (fold change: 16.43±2.30 times; P<0.05). The stemness of hNIS-EGFP-hUCMSCs was found to be slightly decreased but not statistically significant; the overall characteristics of stem cells remained unchanged. The assessments of adipogenic and osteogenic differentiation suggest that hNIS-EGFP-hUCMSCs have no significantly different characteristics compared with primary hUCMSCs.
Collapse
Affiliation(s)
- Yu Meng
- Department of Nephrology, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China
| | - Huanhuan Liu
- Department of Nephrology, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China
| | - Ning Bian
- Department of Cardiovascular Medicine, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China
| | - Jian Gong
- Department of Nuclear Medicine, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China
| | - Xing Zhong
- Department of Nuclear Medicine, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China
| | - Chunrong Huang
- Department of Nephrology, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China
| | - Wenxue Liang
- Department of Nephrology, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China
| | - Hao Xu
- Department of Nephrology, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China.,Department of Nuclear Medicine, The First Hospital Affiliated to Jinan University, Guangzhou, Guangdong 510630, P.R. China
| |
Collapse
|
7
|
Wang C, Timmons CL, Shao Q, Kinlock BL, Turner TM, Iwamoto A, Zhang H, Liu H, Liu B. GB virus type C E2 protein inhibits human immunodeficiency virus type 1 Gag assembly by downregulating human ADP-ribosylation factor 1. Oncotarget 2016; 6:43293-309. [PMID: 26675377 PMCID: PMC4791233 DOI: 10.18632/oncotarget.6537] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2015] [Accepted: 11/21/2015] [Indexed: 12/28/2022] Open
Abstract
GB virus type C (GBV-C) glycoprotein E2 protein disrupts HIV-1 assembly and release by inhibiting Gag plasma membrane targeting, however the mechanism by which the GBV-C E2 inhibits Gag trafficking remains unclear. In the present study, we identified ADP-ribosylation factor 1 (ARF1) contributed to the inhibitory effect of GBV-C E2 on HIV-1 Gag membrane targeting. Expression of GBV-C E2 decreased ARF1 expression in a proteasomal degradation-dependent manner. The restoration of ARF1 expression rescued the HIV-1 Gag processing and membrane targeting defect imposed by GBV-C E2. In addition, GBV-C E2 expression also altered Golgi morphology and suppressed protein traffic through the secretory pathway, which are all consistent with a phenotype of disrupting the function of ARF1 protein. Thus, our results indicate that GBV-C E2 inhibits HIV-1 assembly and release by decreasing ARF1, and may provide insights regarding GBV-C E2's potential for a new therapeutic approach for treating HIV-1.
Collapse
Affiliation(s)
- Chenliang Wang
- Center for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, USA.,Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Department of Clinical Laboratory, Guangdong Institute of Gastroenterology and The Sixth Affiliated Hospital, Institute of Human Virology and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Christine L Timmons
- Center for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, USA
| | - Qiujia Shao
- Center for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, USA
| | - Ballington L Kinlock
- Center for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, USA
| | - Tiffany M Turner
- Center for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, USA
| | - Aikichi Iwamoto
- Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - Hui Zhang
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Department of Clinical Laboratory, Guangdong Institute of Gastroenterology and The Sixth Affiliated Hospital, Institute of Human Virology and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Huanliang Liu
- Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Department of Clinical Laboratory, Guangdong Institute of Gastroenterology and The Sixth Affiliated Hospital, Institute of Human Virology and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Bindong Liu
- Center for AIDS Health Disparities Research, Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, USA
| |
Collapse
|
8
|
Da Mota LD, Nishiya AS, Finger-Jardim F, Barral MFM, Silva CM, Nader MM, Gonçalves CV, Da Hora VP, Silveira J, Basso RP, Soares MA, Levi JE, Martínez AMB. Prevalence of human pegivirus (HPgV) infection in patients carrying HIV-1C or non-C in southern Brazil. J Med Virol 2016; 88:2106-2114. [PMID: 27171504 DOI: 10.1002/jmv.24574] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2016] [Indexed: 11/06/2022]
Abstract
Previous studies have demonstrated that coinfection with HPgV is a protective factor for human immunodeficiency virus (HIV)-infected patients, leading to slower disease progression, and longer survival after established disease. The present study sought to estimate the prevalence of HPgV infection and associated risk factors in patients harboring C or non-C HIV-1 subtypes followed-up at HU-FURG, southern Brazil. Samples from 347 HIV-1-infected subjects were subjected to plasma RNA extraction, cDNA synthesis, HPgV RNA detection, and HIV-1 genotyping. The overall prevalence of HPgV RNA was 34%. Individuals aged 18-30 years had higher chances of infection compared with those 50 years or older (95%CI 1.18-52.36, P = 0.03). The number of sexual partner between one and three was a risk factor for HPgV infection (95%CI 1.54-10.23; P < 0.01), as well as the time since diagnosis of HIV-1 ≥ 11 years (95%CI 1.01-2.89; P = 0.04). Patients infected with HIV non-C subtypes had six times more chance of being HPgV-infected when compared to subtype C-infected subjects (95%CI 2.28-14.78; P < 0.01). This was the first study conducted in southern Brazil to find the circulation of HPgV. HIV/HPgV coinfection was associated with a longer survival among HIV+ patients. Of novelty, individuals infected by HIV non-C subtypes were more susceptible to HPgV infection. However, additional studies are needed to correlate the HIV-1 subtypes with HPgV infection and to clarify cellular and molecular pathways through which such associations are ruled. J. Med. Virol 88:2106-2114, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Luísa Dias Da Mota
- Medical School of the Federal University of Rio Grande, Rio Grande do sul, Brazil.
| | | | | | - Maria F M Barral
- Medical School of the Federal University of Rio Grande, Rio Grande do sul, Brazil
| | - Cláudio M Silva
- Medical School of the Federal University of Rio Grande, Rio Grande do sul, Brazil
| | - Maiba M Nader
- Medical School of the Federal University of Rio Grande, Rio Grande do sul, Brazil
| | | | - Vanusa P Da Hora
- Medical School of the Federal University of Rio Grande, Rio Grande do sul, Brazil
| | - Jussara Silveira
- Medical School of the Federal University of Rio Grande, Rio Grande do sul, Brazil
| | - Rossana P Basso
- Medical School of the Federal University of Rio Grande, Rio Grande do sul, Brazil
| | - Marcelo A Soares
- Genetics Program, National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | | | - Ana M B Martínez
- Medical School of the Federal University of Rio Grande, Rio Grande do sul, Brazil
| |
Collapse
|
9
|
Heat-stable molecule derived from Streptococcus cristatus induces APOBEC3 expression and inhibits HIV-1 replication. PLoS One 2014; 9:e106078. [PMID: 25165817 PMCID: PMC4148350 DOI: 10.1371/journal.pone.0106078] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2013] [Accepted: 07/31/2014] [Indexed: 11/26/2022] Open
Abstract
Although most human immunodeficiency virus type 1 (HIV-1) cases worldwide are transmitted through mucosal surfaces, transmission through the oral mucosal surface is a rare event. More than 700 bacterial species have been detected in the oral cavity. Despite great efforts to discover oral inhibitors of HIV, little information is available concerning the anti-HIV activity of oral bacterial components. Here we show that a molecule from an oral commensal bacterium, Streptococcus cristatus CC5A can induce expression of APOBEC3G (A3G) and APOBEC3F (A3F) and inhibit HIV-1 replication in THP-1 cells. We show by qRT-PCR that expression levels of A3G and A3F increase in a dose-dependent manner in the presence of a CC5A extract, as does A3G protein levels by Western blot assay. In addition, when the human monocytic cell line THP-1 was treated with CC5A extract, the replication of HIV-1 IIIB was significantly suppressed compared with IIIB replication in untreated THP-1 cells. Knock down of A3G expression in THP-1 cells compromised the ability of CC5A to inhibit HIV-1 IIIB infectivity. Furthermore, SupT1 cells infected with virus produced from CC5A extract-treated THP-1 cells replicated virus with a higher G to A hypermutation rate (a known consequence of A3G activity) than virus used from untreated THP-1 cells. This suggests that S. cristatus CC5A contains a molecule that induces A3G/F expression and thereby inhibits HIV replication. These findings might lead to the discovery of a novel anti-HIV/AIDS therapeutic.
Collapse
|
10
|
Kinlock BL, Wang Y, Turner TM, Wang C, Liu B. Transcytosis of HIV-1 through vaginal epithelial cells is dependent on trafficking to the endocytic recycling pathway. PLoS One 2014; 9:e96760. [PMID: 24830293 PMCID: PMC4022679 DOI: 10.1371/journal.pone.0096760] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 03/21/2014] [Indexed: 01/03/2023] Open
Abstract
Background While it is accepted that viruses can enter epithelial cells by endocytosis, the lack of an established biological mechanism for the trafficking of infectious virions through vaginal epithelial cells and their release from the plasma membrane has contributed to ongoing controversy about whether endocytosis is a mere artifact of some cell culture systems and whether squamous vaginal epithelial cells are even relevant as it pertains to HIV-1 transmission. Methodology/Principal Findings In this study, we investigated the intracellular trafficking pathway that HIV-1 exploits to transcytose vaginal epithelial cells. The reduction of endosome tubulation by recycling endosome inhibitors blocked transcytosis of HIV-1 in a cell culture and transwell system. In addition, we demonstrate that although heat-inactivated virus was endocytosed as efficiently as native virus, heat-inactivated virus was trafficked exclusively to the lysosomal pathway for degradation following endocytosis. Lysosomal protease-specific inhibitors blocked the degradation of inactivated virions. Immunofluorescence analysis not only demonstrated that HIV-1 was inside the cells but the different colocalization pattern of native vs. heat inactivated virus with transferrin provided conclusive evidence that HIV-1 uses the recycling pathway to get across vaginal epithelial cells. Conclusions/Significance Altogether, our findings demonstrate the precise intracellular trafficking pathway utilized by HIV-1 in epithelial cells, confirms that HIV-1 transcytosis through vaginal epithelial cells is a biological phenomenon and brings to light the differential intracellular trafficking of native vs heat-inactivated HIV-1 which with further exploration could prove to provide valuable insights that could be used in the prevention of transcytosis/transmission of HIV-1 across the mucosal epithelia.
Collapse
Affiliation(s)
- Ballington L. Kinlock
- Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, Tennessee, United States of America
- Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, United States of America
| | - Yudi Wang
- Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, Tennessee, United States of America
| | - Tiffany M. Turner
- Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, Tennessee, United States of America
- Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, United States of America
| | - Chenliang Wang
- Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, Tennessee, United States of America
- Institute of Gastroenterology and Institute of Human Virology, Sun Yat-sen University, Guangzhou, Guangdong, Peoples of Republic of China
| | - Bindong Liu
- Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, Tennessee, United States of America
- Department of Microbiology and Immunology, Meharry Medical College, Nashville, Tennessee, United States of America
- * E-mail:
| |
Collapse
|
11
|
Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors. Virology 2014; 456-457:300-9. [PMID: 24889249 DOI: 10.1016/j.virol.2014.03.018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2014] [Revised: 03/08/2014] [Accepted: 03/17/2014] [Indexed: 11/20/2022]
Abstract
We previously found that human pegivirus (HPgV; formerly GBV-C) NS3 protease activity inhibits Human Immunodeficiency Virus (HIV) replication in a CD4+ T cell line. Given the protease׳s similarity to the Hepatitis C virus (HCV) NS3 protease, we characterized HPgV protease activity and asked whether it affects the type I interferon response or is inhibited by HCV protease antagonists. We characterized the activity of proteases with mutations in the catalytic triad and demonstrated that the HCV protease inhibitors Telaprevir, Boceprevir, and Danoprevir do not affect HPgV protease activity. HPgV NS3 protease cleaved MAVS but not TRIF, and it inhibited interferon responses sufficiently to enhance growth of an interferon-sensitive virus. Therefore, HPgV׳s inhibition of the interferon response could help promote HPgV persistence, which is associated with clinical benefits in HIV-infected patients. Our results also imply that HCV protease inhibitors should not interfere with the beneficial effects of HPgV in HPgV/HCV/HIV infected patients.
Collapse
|
12
|
Lee CK, Tang JWT, Chiu L, Loh TP, Olszyna D, Chew N, Archuleta S, Koay ESC. Epidemiology of GB virus type C among patients infected with HIV in Singapore. J Med Virol 2014; 86:737-44. [DOI: 10.1002/jmv.23893] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/09/2014] [Indexed: 11/08/2022]
Affiliation(s)
- Chun Kiat Lee
- Molecular Diagnosis Centre, Department of Laboratory Medicine; National University Hospital; Singapore
| | - Julian Wei-Tze Tang
- Alberta Provincial Laboratory for Public Health; University of Alberta Hospital; Edmonton Canada
- Department of Medical Microbiology and Immunology; University of Alberta; Edmonton Canada
| | - Lily Chiu
- Molecular Diagnosis Centre, Department of Laboratory Medicine; National University Hospital; Singapore
| | - Tze Ping Loh
- Clinical Chemistry; Department of Laboratory Medicine; National University Hospital; Singapore
| | - Dariusz Olszyna
- Department of Medicine; Yong Loo Lin School of Medicine; National University of Singapore; Singapore
- Division of Infectious Diseases; University Medicine Cluster; National University Hospital; Singapore
| | - Nicholas Chew
- Department of Medicine; Yong Loo Lin School of Medicine; National University of Singapore; Singapore
- Division of Infectious Diseases; University Medicine Cluster; National University Hospital; Singapore
| | - Sophia Archuleta
- Department of Medicine; Yong Loo Lin School of Medicine; National University of Singapore; Singapore
- Division of Infectious Diseases; University Medicine Cluster; National University Hospital; Singapore
| | - Evelyn Siew-Chuan Koay
- Molecular Diagnosis Centre, Department of Laboratory Medicine; National University Hospital; Singapore
- Department of Pathology; Yong Loo Lin School of Medicine; National University of Singapore; Singapore
| |
Collapse
|
13
|
Ghai RR, Sibley SD, Lauck M, Dinis JM, Bailey AL, Chapman CA, Omeja P, Friedrich TC, O'Connor DH, Goldberg TL. Deep sequencing identifies two genotypes and high viral genetic diversity of human pegivirus (GB virus C) in rural Ugandan patients. J Gen Virol 2013; 94:2670-2678. [PMID: 24077364 DOI: 10.1099/vir.0.055509-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Human pegivirus (HPgV), formerly 'GB virus C' or 'hepatitis G virus', is a member of the genus Flavivirus (Flaviviridae) that has garnered significant attention due to its inhibition of HIV, including slowing disease progression and prolonging survival in HIV-infected patients. Currently, there are six proposed HPgV genotypes that have roughly distinct geographical distributions. Genotypes 2 and 3 are the most comprehensively characterized, whereas those genotypes occurring on the African continent, where HPgV prevalence is highest, are less well studied. Using deep sequencing methods, we identified complete coding HPgV sequences in four of 28 patients (14.3%) in rural Uganda, east Africa. One of these sequences corresponds to genotype 1 and is the first complete genome of this genotype from east Africa. The remaining three sequences correspond to genotype 5, a genotype that was previously considered exclusively South African. All four positive samples were collected within a geographical area of less than 25 km(2), showing that multiple HPgV genotypes co-circulate in this area. Analysis of intra-host viral genetic diversity revealed that total single-nucleotide polymorphism frequency was approximately tenfold lower in HPgV than in hepatitis C virus. Finally, one patient was co-infected with HPgV and HIV, which, in combination with the high prevalence of HIV, suggests that this region would be a useful locale to study the interactions and co-evolution of these viruses.
Collapse
Affiliation(s)
- Ria R Ghai
- Department of Biology, McGill University, Montreal, QC, Canada
| | - Samuel D Sibley
- Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, USA
| | - Michael Lauck
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - Jorge M Dinis
- Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, USA
| | - Adam L Bailey
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - Colin A Chapman
- Department of Anthropology and McGill School of Environment, Montreal, QC, Canada, and Wildlife Conservation Society, NY, USA
| | - Patrick Omeja
- Makerere University Biological Field Station, Fort Portal, Uganda
| | - Thomas C Friedrich
- Wisconsin National Primate Research Center, Madison, WI, USA
- Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, USA
| | - David H O'Connor
- School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA
| | - Tony L Goldberg
- Wisconsin National Primate Research Center, Madison, WI, USA
- Makerere University Biological Field Station, Fort Portal, Uganda
- Department of Pathobiological Sciences, University of Wisconsin-Madison, Madison, WI, USA
| |
Collapse
|